NGM Biopharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
NGM Biopharmaceuticals CEO'su David Woodhouse, Sep2018 tarihinde atandı, in görev süresi 5.58 yıldır. in toplam yıllık tazminatı $ 5.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.3% maaş ve 89.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler $ 179.29K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 5.6 yıldır.
Anahtar bilgiler
David Woodhouse
İcra Kurulu Başkanı
US$5.9m
Toplam tazminat
| CEO maaş yüzdesi | 10.3% |
| CEO görev süresi | 5.6yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 1.3yrs |
| Yönetim Kurulu ortalama görev süresi | 5.6yrs |
Son yönetim güncellemeleri
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$142m |
| Sep 30 2023 | n/a | n/a | -US$151m |
| Jun 30 2023 | n/a | n/a | -US$170m |
| Mar 31 2023 | n/a | n/a | -US$178m |
| Dec 31 2022 | US$6m | US$610k | -US$163m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$135m |
| Mar 31 2022 | n/a | n/a | -US$125m |
| Dec 31 2021 | US$10m | US$580k | -US$120m |
| Sep 30 2021 | n/a | n/a | -US$121m |
| Jun 30 2021 | n/a | n/a | -US$122m |
| Mar 31 2021 | n/a | n/a | -US$111m |
| Dec 31 2020 | US$5m | US$525k | -US$102m |
| Sep 30 2020 | n/a | n/a | -US$90m |
| Jun 30 2020 | n/a | n/a | -US$72m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$2m | US$490k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$13m |
| Jun 30 2019 | n/a | n/a | -US$9m |
| Mar 31 2019 | n/a | n/a | -US$5m |
| Dec 31 2018 | US$4m | US$413k | -US$493k |
Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 5.93M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 655.02K ).
Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
David Woodhouse (52 yo)
5.6yrs
Görev süresi
US$5,933,500
Tazminat
Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman of the Board of Directors | 13.5yrs | US$1.10m | 3.32% $ 4.3m | |
| CEO & Director | 5.6yrs | US$5.93m | 0.14% $ 179.3k | |
| Senior VP | 4.5yrs | US$2.10m | 0.022% $ 28.7k | |
| Chief Medical Officer & Executive VP | 5.1yrs | US$2.73m | 0.017% $ 22.3k | |
| Chief Financial Officer | 1.3yrs | Veri yok | Veri yok | |
| VP, Corporate Controller & Principal Accounting Officer | less than a year | Veri yok | 0.011% $ 13.8k | |
| Chief Scientific Officer | 1.3yrs | Veri yok | Veri yok | |
| Director of People & Culture | less than a year | Veri yok | Veri yok | |
| Head of Business Development | 1.8yrs | Veri yok | Veri yok | |
| Senior Director & Head of Biology | 1.3yrs | Veri yok | Veri yok | |
| Senior Vice President of CMC & Process Development | less than a year | Veri yok | Veri yok |
1.3yrs
Ortalama Görev Süresi
56.5yo
Ortalama Yaş
Deneyimli Yönetim: NGM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman of the Board of Directors | 13.5yrs | US$1.10m | 3.32% $ 4.3m | |
| CEO & Director | 5.6yrs | US$5.93m | 0.14% $ 179.3k | |
| Special Advisor | no data | Veri yok | Veri yok | |
| Special Advisor | no data | Veri yok | Veri yok | |
| Lead Independent Director | 5.6yrs | US$270.23k | 19.87% $ 25.5m | |
| Chairman of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 2.8yrs | US$250.00k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$273.09k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.7yrs | US$265.00k | 0.0084% $ 10.8k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
5.6yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: NGM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).